

6-12-2022

SARS-CoV-2 and Ebola: CHO-based manufacturing provides high quality subunit-vaccine candidates and diagnostics

Paco Pino
ExcellGene SA, Switzerland

Follow this and additional works at: https://dc.engconfintl.org/vaccine_viii

Recommended Citation

Paco Pino, "SARS-CoV-2 and Ebola: CHO-based manufacturing provides high quality subunit-vaccine candidates and diagnostics" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/4

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Vaccine Technology VIII by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

**SARS-CoV-2 AND EBOLA: CHO-BASED MANUFACTURING PROVIDES HIGH QUALITY SUBUNIT-
VACCINE CANDIDATES AND DIAGNOSTICS**

Paco Pino, ExcellGene SA, Switzerland
paco.pino@excellgene.com